TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05283369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videogame therapy
Description: The usual dose of conventional physical therapy, plus 300 minutes a week of in-home videogame therapy for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: The usual dose of physical and occupational therapy, for 8 weeks.
Study: NCT05601778

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the placebo comparator of study
Study: NCT06453824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDI-2517
Description: study drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDI-2517
Description: study drug
Study: NCT04885595

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forceps biopsy and cryobiopsy
Description: Once the nodule is visualized by radial EBUS, the position of the probe in relation to the lesion is noted. Routinely, forceps biopsy and cryobiopsy are used serially in each patient within the same session.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forceps biopsy and cryobiopsy
Description: Once the nodule is visualized by radial EBUS, the position of the probe in relation to the lesion is noted. Routinely, forceps biopsy and cryobiopsy are used serially in each patient within the same session.
Study: NCT06488170

Intervention type: DRUG
Intervention: Tildrakizumab
Description: As provided in real world clinical practice.
Study: NCT05955599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACL Injury Prevention Training
Description: Supervised ACL injury prevention training twice a week (2 x 15 minutes) over an 8-week period.
Study: NCT06453824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDI-2517
Description: study drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDI-2517
Description: study drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDI-2517
Description: study drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDI-2517
Description: study drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDI-2517
Description: study drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDI-2517
Description: study drug

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: matching placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: matching placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT05955599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACL Injury Prevention Training
Description: Supervised ACL injury prevention training twice a week (2 x 15 minutes) over an 8-week period.

Intervention type: OTHER
Group type: OTHER
Intervention: Control - Shoulder Injury Prevention Training
Description: Supervised shoulder injury prevention training twice a week (2 x 15 minutes) over an 8-week period.

Intervention type: OTHER
Group type: OTHER
Intervention: Control - Shoulder Injury Prevention Training
Description: Supervised shoulder injury prevention training twice a week (2 x 15 minutes) over an 8-week period.
Study: NCT05015517

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plain block
Description: Patients will be placed in the lateral position.Ultrasonography will be performed by an experienced anesthetist.The 4th lumbar vertebral level will be determined using the conventional method (imaginary line between two iliac crests). The low frequency convex probe (2-5MHz) will then be placed at the mid-vertebral line in the sagittal plane. It will be shifted from the midline, 3.5-4 cm lateral to the side of the surgery to visualize the erector spinae muscle and transverse process. Using the out-plane technique a 22G/80-mm block needle will be advanced until it reaches the transverse process. After negative aspiration, 0.5-1 ml of the prepared local anaesthetic solution (20 ml bupivacaine 0.5%, 10 ml lidocaine 2%) and 10 ml normal saline will be administered for hydrodissection to confirm correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurred when injecting local anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia Iliaca block
Description: Patients will be placed in supine position. Ultrasonography will be performed by an experienced anesthetist using ultrasound device equipped with a low frequency (2-5 MHz) convex probe and an echogenic 21 G/ 10 cm needle will be used.~The probe will be placed in the inguinal crease. Scan will be started laterally from the femoral artery and nerve in the inguinal crease to identify the Sartorius muscle. The muscle will then be traced until its origin at the anterior superior iliac spine is identified and the shadow of the bony of iliac crest \& iliacus muscle will be seen. Injection will be performed at the plane deep to the fascia iliaca and above the lateral part of the iliacus muscle. After negative aspiration, the prepared local anaesthetic solution (15 ml bupivacaine 0.5%, 15 ml normal saline) will be injected incrementally, aspirating every 5 ml.
Study: NCT04816825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alkit eSence
Description: Home-based rehabilitation program including computer games and supervised by a physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation
Description: Standard rehabilitation program at the COPD-Center
Study: NCT06453824

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: matching placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: matching placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: matching placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT06514105

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy program
Description: All patients participating in the study will be included in the physiotherapy program. Physiotherapy program consist of hot-pack (for 15 minutes), ultrasound (Continuous ultrasound, for 5 minutes, 1-MHZ 1.5W/cm2, a 5-cm ultrasound head on the subacromial region),TENS (for 20 minutes with the BTL 4000 combined device) and exercise program (Stretching exercises for the rotator cuff, rhomboid muscles, levator scapula, serratus anterior and pectoaral muscles and strengthening the muscles around the shoulder with a resistance exercise band selected in a color appropriate to the patient's strength).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy program
Description: All patients participating in the study will be included in the physiotherapy program. Physiotherapy program consist of hot-pack (for 15 minutes), ultrasound (Continuous ultrasound, for 5 minutes, 1-MHZ 1.5W/cm2, a 5-cm ultrasound head on the subacromial region),TENS (for 20 minutes with the BTL 4000 combined device) and exercise program (Stretching exercises for the rotator cuff, rhomboid muscles, levator scapula, serratus anterior and pectoaral muscles and strengthening the muscles around the shoulder with a resistance exercise band selected in a color appropriate to the patient's strength).
Study: NCT06453824

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT05656690

Intervention type: OTHER
Intervention: Exposure to disability
Description: Disability status assessed by functional measures

Intervention type: OTHER
Intervention: Exposure to disability
Description: Disability status assessed by functional measures
Study: NCT06514105

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity laser
Description: High intensity laser will be applied using the BTL-6000 (BTL Company, UK) device. The first 5 sessions will be applied to the painful area by making circular movements from the center to the outside for 100 seconds at a power of 10W and a dose of 10 J/cm2 (analgesic effect). The last 5 sessions will be applied to the painful area with linear movements at 4W power and 100 J/cm2 dose (biostimulation effect) for 10 minutes and 25 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham high intensity laser
Description: In sham application, the patient will be positioned on the treatment stretcher and the device will be turned on. The guide light of the high-intensity laser device, which gives the same color as the laser light, will be applied to the subacromial region in circular movements from outside to inside and from inside to outside.
Study: NCT05743699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright Horizons
Description: Bright Horizons is a brief substance use intervention delivered by Research Program Assistants.
Study: NCT02944955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLEX 404 Oral Liquid
Description: BLEX 404 Oral Liquid is orally administered twice daily in combination with azacitdine treatment cycles (2 cycles in Part I and 6 cycles in Part II).~Azacitidine treatment: SC or IV injections at 75 mg/m2, QD for 7 days each cycle. 28 days/cycle, and repeat cycles every 4 weeks.
Study: NCT05743699

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Case Management
Description: Placebo condition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case Management
Description: Placebo condition
Study: NCT04820582

Intervention type: OTHER
Intervention: Delphi Questionnaire
Description: Evaluation of a list of PROMs and CROMs specific for endometriosis (previously selected from a litterature review) on a Likert scale of 1 to 9 for their relevance and feasibility
Study: NCT04617600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTA
Description: Survival rate using MTA in cariously exposed vital primary molars

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TheraCal PT
Description: Survival rate using TheraCal PT in cariously exposed vital primary molars
Study: NCT03766750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIMA association
Description: 1 coated tablet, oral, once a day.
Study: NCT04837313

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation
Study: NCT03766750

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tradjenta
Description: 1 coated tablet, oral, once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Forxiga
Description: 1 coated tablet, oral, once a day.
Study: NCT05164861

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: kombucha-based beverage
Description: kombucha-based beverage: drinking water, black tea, kombucha, inulin, vitamins (B1, B2, B6, niacin, folic acid). Nutritional value in 100 ml: carbohydrates - 2.57 g (including sucrose - 0.22 g, glucose - 1.32 g, fructose - 1.03 g), inulin - 1.15 g (46%\*), vitamin B1 - 0.4 mg (29%\*), B2 - 0.21 mg (13%\*), B6 - 0.48 mg (24%\*), niacin - 2.74 mg (15%\*), folic acid - 24.0 mcg (12%\*). Energy value/Caloric content - 54 kilojoules/13 kcal (\* - % of the recommended daily allowance, according to the Technical regulations of the Customs Union #022/2011). Flavours, identical by nutrient's content and nutrients density: black currant berries \& juniper berries, or strawberries \& lime leaves, or passion fruit \& mango.~Portion's volume - 220 ml. Daily intake: 1 portion
Study: NCT05722236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IBD Strong Peer2Peer
Description: Mentee participants will experience the intervention: this group will partake in peer-led sessions (peer calls) consisting of up to 10 virtual sessions on Zoom lasting approximately 20-30 minutes in duration over eight weeks. Individual peer calls will be unstructured whereby trained mentors (patients with IBD who have undergone training to be a mentor) and mentees will be given the freedom to discuss whatever issues they choose. Psychological and emotional support is provided to the mentee by the mentor.

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist control
Description: Wait list controls will be offered participation in the IBD Strong Peer2Peer intervention once post-control outcome measures have been completed.
Study: NCT05260931

Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal echocardiography
Description: Two-dimensional, M mode, and Doppler echocardiographic examination performed to rule out cardiac defects and to evaluate cardiac morphometry and function. Cardiac, thoracic, and ventricular areas and diameters measured on 2-dimensional images from an apical or basal four-chamber (4 ChV) view at end diastole. Ventricular sphericity indices calculated by dividing the longitudinal by basal-transverse ventricular diameters. Atrial areas at maximum distension at end of systole. Atria and ventricle to-heart ratios calculated. Myocardial wall thicknesses and ventricular shortening/ejection fractions obtained from M-mode transverse 4 ChV. MAPSE/TAPSE assessed by M-mode from an apical or basal 4 ChV. Mitral and tricuspid early and late ventricular filling obtained by Doppler, and E/A ratios calculated. Left and right myocardial performance indices obtained from Doppler spectrum in a cross-sectional image of the thorax.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal echocardiography
Description: Two-dimensional, M mode, and Doppler echocardiographic examination performed to rule out cardiac defects and to evaluate cardiac morphometry and function. Cardiac, thoracic, and ventricular areas and diameters measured on 2-dimensional images from an apical or basal four-chamber (4 ChV) view at end diastole. Ventricular sphericity indices calculated by dividing the longitudinal by basal-transverse ventricular diameters. Atrial areas at maximum distension at end of systole. Atria and ventricle to-heart ratios calculated. Myocardial wall thicknesses and ventricular shortening/ejection fractions obtained from M-mode transverse 4 ChV. MAPSE/TAPSE assessed by M-mode from an apical or basal 4 ChV. Mitral and tricuspid early and late ventricular filling obtained by Doppler, and E/A ratios calculated. Left and right myocardial performance indices obtained from Doppler spectrum in a cross-sectional image of the thorax.
Study: NCT05057273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT-11
Description: Oral once daily tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: Biologic
Study: NCT06662019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-IP-00001 inhalation solution
Description: Multiple ascending dose (MAD) study. Over the 2 dosing days participants will receive a total of 6 inhaled doses of 5 ml of N-IP-00001 at increasing concentrations, ranging from 0.5mg/ml to 16mg/ml (total volume loaded in the nebuliser is 6 ml per dose).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl isotonic saline solution
Description: Nebulized treatment consisting of 0.9% saline solution.
Study: NCT05001828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Description: ADI-PEG 20 in combination with venetoclax and azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Description: ADI-PEG 20 in combination with venetoclax and azacitidine
Study: NCT05616559

Intervention type: COMBINATION_PRODUCT
Intervention: Treatment Package for First-Episode Depression
Description: The outpatient 'treatment package' for first episode depression is a national uniform package designed by Mental Health Services in the Capital Region. The treatment package for first-episode depression is a program with manualized group CBT, psychoeducation of patients and relatives, and relapse prevention. Antidepressant medication and individual psychotherapy are available as needed.

Intervention type: COMBINATION_PRODUCT
Intervention: Treatment Package for First-Episode Depression
Description: The outpatient 'treatment package' for first episode depression is a national uniform package designed by Mental Health Services in the Capital Region. The treatment package for first-episode depression is a program with manualized group CBT, psychoeducation of patients and relatives, and relapse prevention. Antidepressant medication and individual psychotherapy are available as needed.

Intervention type: COMBINATION_PRODUCT
Intervention: Treatment Package for First-Episode Depression
Description: The outpatient 'treatment package' for first episode depression is a national uniform package designed by Mental Health Services in the Capital Region. The treatment package for first-episode depression is a program with manualized group CBT, psychoeducation of patients and relatives, and relapse prevention. Antidepressant medication and individual psychotherapy are available as needed.
Study: NCT04667065

Intervention type: OTHER
Group type: OTHER
Intervention: Physical activity
Description: Physical activity with the remotely guidance of physical activity teachers
Study: NCT05613257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Distal targeting jig
Description: Patients in this arm will have an assistive targeting device used for interlocking screw placement. The targeting device is attached to the nail proximally or distally (for antegrade or retrograde nailing, respectively) to guide screw placement through the other end of the intramedullary device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free-hand/perfect circles technique
Description: Patients in this arm will have no assistive targeting device use and the surgeon will use a free-hand technique for the placement of interlocking screws. With this technique, fluoroscopic images are taken such that the interlocking holes of the intramedullary device are perfect circles and indicate that a screw introduced in the same plane that the fluoroscopic image was taken would seat perpendicularly to the intramedullary device. This is the most commonly employed technique for interlocking screw placement through intramedullary devices.
Study: NCT04950855

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography,Optical Coherence Tomography Angiography(Topcon)
Description: Optical coherence tomography optical coherence tomography angiography
Study: NCT05722028

Intervention type: PROCEDURE
Intervention: hysteroscopy
Description: Surgical hysteroscopy without anaesthesia for removal of uterine polyp / retained products of conception.
Study: NCT04291508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Acetaminophen (room temperature)
Description: Acetaminophen given intravenously at the dose of 1 gram (or 15 mg/kg if patient weighs \< 50 kg) every six hours for 5 days (20 doses)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Vitamin C (refrigerated)
Description: Vitamin C given intravenously at the dose of 50 mg/kg every six hours for 5 days (20 doses)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Dextrose (room temperature)
Description: Placebo (identical appearing room temperature 5% dextrose solution) infused every six hours for 5 days (20 doses)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Dextrose refrigerated
Description: Placebo (identical appearing refrigerated 5% dextrose solution) infused every six hours for 5 days (20 doses)
Study: NCT05444543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Participants will cycle topical steroid in a three-months on three-months off fashion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Participants will cycle topical steroid in a three-months on three-months off fashion
Study: NCT06212193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trillium™
Description: Trillium™ Stent Graft for Cross-Caval Tricuspid Valve Replacement
Study: NCT05108259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBP1502
Description: 40 mg/0.4 mL single SC injection via PFS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-licensed Humira
Description: 40 mg/0.4 mL single SC injection via PFS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed Humira
Description: 40 mg/0.4 mL single SC injection via PFS
Study: NCT05753813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phexxi
Description: intravaginal gel twice weekly for 4 weeks.
Study: NCT05517096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-Health
Description: In the intervention phase asthma care is provided on an at-needed-basis via online communication and is always available during working hours.
Study: NCT05858775

Intervention type: DEVICE
Intervention: Pregnolia System
Description: Cervical stiffness assessment with the Pregnolia System at 3 locations on the uterine cervix.

Intervention type: DEVICE
Intervention: Pregnolia System
Description: Cervical stiffness assessment with the Pregnolia System at 3 locations on the uterine cervix.
Study: NCT05743634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YY001
Description: Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
Study: NCT04674683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBI-8000 in combination with nivolumab
Description: Patients will take 30 mg of HBI-8000 orally approximately 30 minutes after a full meal, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab IV will be administered by intravenous infusion at specific doses on specific days in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice. In adolescent patients with body weight \< 40 kg, nivolumab will be dosed at specific doses on specific days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in combination with nivolumab
Description: Patients will take 30 mg of Placebo orally approximately 30 minutes after a full meal, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab IV at specific doses will be administered by intravenous infusion in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice.
Study: NCT05918341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piracetam
Description: Subtherapeutic dose of piracetam (once-weekly doses of 7.5 mg, 5 mg, 2.5 mg and 1.25 mg)
Study: NCT06106334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S309309
Description: Administered as oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered as oral capsules